MXD1、Ki67在乳腺浸润性导管癌中的表达及其与临床病理特征的关系  

Expression of MXD1 and Ki-67 in breast invasive ductal carcinoma and their relationship with clinicopathologic features

作　　者：张待翼 韩国晖[2] 徐树明[3] Zhang Daiyi;Han Guohui;Xu Shuming(Department of Breast Surgery,Maternal and Child Health Hospital of Shanxi Province,Taiyuan 030013,China;Department of Breast Surgery,Shanxi Cancer Hospital,Taiyuan 030013,China;Medical Imaging Center,Maternal and Child Health Hospital of Shanxi Province,Taiyuan 030013,China)

机构地区：[1]山西省妇幼保健院乳腺外科,太原030013 [2]山西省肿瘤医院乳腺外科,太原030013 [3]山西省妇幼保健院医学影像中心,太原030013

出　　处：《中华内分泌外科杂志（中英文）》2024年第5期629-633,共5页Chinese Journal of Endocrine Surgery

基　　金：山西省基础研究计划(202103021224436)。

摘　　要：目的分析MAX二聚化蛋白1(MAX dimerization protein 1,MXD1)、Ki67在乳腺浸润性导管癌(breast invasive ductal carcinoma,IDC)中的表达及其与临床病理特征的关系。方法回顾性分析2022年3月至2023年3月在山西省妇幼保健院及山西省肿瘤医院收治的68例乳腺浸润性导管癌患者的临床资料,测定乳腺浸润性导管癌患者癌组织及癌旁正常组织中的MXD1、Ki67表达情况,并分析不同临床病理特征患者癌组织中的MXD1、Ki67表达情况;MXD1、Ki67表达与临床病理特征的关系;随访至2024年3月,分析不同MXD1、Ki67表达患者的生存情况。结果68例患者癌组织中的MXD1高表达、Ki67阳性占比分别为63.24%、69.12%,明显高于正常组织的8.82%、11.76%(χ^(2)=43.67、46.43,P<0.05)。组织学Ⅲ级、低分化、TNM分期Ⅲ或Ⅳ期的MXD1高表达、Ki67阳性占比明显高于组织学Ⅰ或Ⅱ级、中高分化、TNM分期Ⅰ或Ⅱ期(χ^(2)=4.05、5.87、6.00、4.00、5.78、5.39,P<0.05),且MXD1、Ki67表达与组织学分级、TNM分期呈正比,与分化程度呈反比(r=0.34、0.39、0.39、0.38、-0.39、-0.34,P<0.05)。不同MXD1、Ki67表达的生存曲线比较,差异有统计学意义(Log-Rankχ^(2)=10.13、10.72,P<0.05)。截至随访终点,MXD1低、高表达的中位生存时间分别为17个月(95%CI:15.059~18.941)、14个月(95%CI:12.452~15.548),Ki67表达阴性、阳性的中位生存时间分别为19个月(95%CI:13.335~24.665)、14个月(95%CI:12.432~15.568)。结论乳腺浸润性导管癌患者MXD1呈高表达状态,Ki67阳性率较高,且与组织学分级、TNM分期、分化程度及生存时间有关。ObjectiveTo analyze the expression of MXD1 and Ki-67 in breast invasive ductal carcinoma(IDC)and their relationship with clinicopathologic features.MethodsClinical data of 68 patients with breast invasive ductal carcinoma admitted to Shanxi Maternal and Child Health Hospital and Shanxi Cancer Hospital from Mar.2022 to Mar.2023 were retrospectively analyzed,and the expressions of MXD1 and Ki67 in cancer tissues and adjacent normal tissues of patients with breast invasive ductal carcinoma were measured.The expressions of MXD1 and Ki67 in cancer tissues of patients with different clinicopathological characteristics were analyzed.The relationship between the expression of MXD1 and Ki67 and clinicopathological features;Follow-up until March 2024 was conducted to analyze the survival of different expressions of MXD1 and Ki67.ResultsThe high expression of MXD1 and positive Ki67 in cancer tissues of 68 patients were 63.24%and 69.12%,respectively,which were significantly higher than 8.82%and 11.76%in normal tissues(χ^(2)=43.67,46.43,P<0.05).The proportion of high expression of MXD1 and Ki67 positive in histological gradeⅢ,low differentiation,TNM stageⅢorⅣwas significantly higher than that in histological gradeⅠorⅡ,middle and high differentiation,TNM stageⅠorⅡ(χ^(2)=4.05,5.87,6.00,4.00,5.78,5.39,P<0.05).The expressions of MXD1 and Ki67 were positively correlated with histological grade and TNM stage,and inversely correlated with differentiation degree(r=0.34,0.39,0.39,0.38,-0.39,-0.34,P<0.05).The survival curves of different expressions of MXD1 and Ki67 were statistically significant(Log-Rankχ^(2)=10.13,10.72,P<0.05).At the end of follow-up,the median survival time of low and high expression of MXD1 was 17 months(95%CI:15.059-18.941)and 14 months(95%CI:12.452-15.548),respectively,and the median survival time of negative and positive expression of Ki67 was 19 months(95%CI:13.335-24.665),14 months(95%CI:12.432-15.568).ConclusionMXD1 is highly expressed and Ki67 positiverate is higher in patients with breast

关 键 词：乳腺浸润性导管癌 乳腺癌 MAX二聚化蛋白1 KI67 

分 类 号：R737.9[医药卫生—肿瘤]